Patent(s) and the Corresponding Patented Drug(s) |
Top |
World Intellectual Property Organization (WIPO) |
Patent ID |
WO2016097869 |
Title |
Fused Ring Heteroaryl Compounds and Their Use As Trk Inhibitors. |
Abstract |
The disclosure provides novel chemical compounds represented by Formula (I) or a pharmaceutically acceptable salt, solvate, polymorph, ester, tautomer or prodrug thereof. The compounds can be used as an inhibitor of Trk and are useful in the treatment of pain, cancer, inflammation, neurodegenerative disease and certain infectious diseases. In some compounds of Formula I, Q is -CH=CR3C(O)Nr4R5, -C=CC(O)NR4R5,-CCC(0)NR4R5, or (II). |
Applicant(s) |
Cmg Pharmaceutical Co., Ltd |
Representative Drug(s) |
D06NPZ |
Drug Info
|
IC50 < 10 nM |
Click to Show More |
[1] |
2
|
D0D6UF
|
Drug Info
|
IC50 < 10 nM
|
[1] |
3
|
D0U2GJ
|
Drug Info
|
IC50 < 10 nM
|
[1] |
Patent ID |
WO2016054807 |
Title |
Trka Kinase Inhibitors, Compositions and Methods Thereof. |
Abstract |
The present invention is directed to substituted indole compounds of formula (I) which are tropomyosin-related kinase (Trk) family protein kinase inhibitors, and hence are useful in the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, adisease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor TrkA. |
Applicant(s) |
Merck Sharp & Dohme Corp |
Representative Drug(s) |
D0BO1H |
Drug Info
|
IC50 = 0.5 nM |
Click to Show More |
[2] |
2
|
D00EUL
|
Drug Info
|
IC50 = 0.7 nM
|
[2] |
3
|
D08CZY
|
Drug Info
|
IC50 = 4.5 nM
|
[2] |
4
|
D00MGO
|
Drug Info
|
IC50 = 610 nM
|
[2] |
5
|
D0LK8E
|
Drug Info
|
IC50 = 1600 nM
|
[2] |
Patent ID |
WO2016020784 |
Title |
N-Acylpyrrolidine Ether Tropomyosin-Related Kinase Inhibitors. |
Abstract |
The present invention relates to compounds of Formula I described herein and their pharmaceutically acceptable salts, and their use in medicine, in particular as Trk antagonists. |
Applicant(s) |
Pfizer Inc |
Representative Drug(s) |
D0X4LA |
Drug Info
|
IC50 = 12 nM |
Click to Show More |
[2] |
2
|
D08BIH
|
Drug Info
|
IC50 = 1300 nM
|
[2] |
Patent ID |
WO2015175788 |
Title |
1-((3S,4R)-4-(3-Fluorophenyl)-1-(2-Methoxyethyl)Pyrrolidin-3-Yl)-3-(4-Methyl-3-(2-Methylpyrimidin-5-Yl)-1-Phenyl-1H-Pyrazol-5-Yl)Urea As A Trka Kinase Inhibitor. |
Abstract |
Provided is Compound (I) or a pharmaceutically acceptable salt thereof, which is an inhibitor of TrkA kinase and is useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation and inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis, pelvic pain syndrome, diseases related to an imbalance of the regulation of bone remodeling, and diseases resulting from Connective Tissue Growth Factor aberrant signaling. |
Applicant(s) |
Array Biopharma Inc |
Representative Drug(s) |
D0P3VK |
Drug Info
|
IC50 = 1.1 nM |
Click to Show More |
[1] |
2
|
D0T5OF
|
Drug Info
|
IC50 = 1.5 nM
|
[1] |
3
|
D0D7EG
|
Drug Info
|
IC50 = 1.7 nM
|
[1] |
Patent ID |
WO2015148373 |
Title |
Trka Kinase Inhibitors, Compositions and Methods Thereof. |
Abstract |
The present invention is directed to a bicyclic heteroaryl benzamide compounds of formula (I) which are tropomyosin-related kinase (Trk) family protein kinase inhibitors, and hence are useful in the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor TrkA. |
Applicant(s) |
Merck Sharp & Dohme Corp |
Representative Drug(s) |
D0N6NG |
Drug Info
|
IC50 = 0.34 nM |
Click to Show More |
[2] |
2
|
D07AJO
|
Drug Info
|
IC50 = 0.79 nM
|
[2] |
3
|
D0DY5R
|
Drug Info
|
IC50 = 0.96 nM
|
[2] |
4
|
D0KC8X
|
Drug Info
|
IC50 = 1.7 nM
|
[2] |
5
|
D07CPL
|
Drug Info
|
IC50 = 1000 nM
|
[2] |
Patent ID |
WO2015148354 |
Title |
Trka Kinase Inhibitors, Compositions and Methods Thereof. |
Abstract |
The present invention is directed to a bicyclic heteroaryl benzamide compounds of formula (I) which are tropomyosin-related kinase (Trk) family protein kinase inhibitors, and hence are useful in the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor TrkA. |
Applicant(s) |
Merck Sharp & Dohme Corp |
Representative Drug(s) |
D0O0GZ |
Drug Info
|
IC50 = 0.16 nM |
Click to Show More |
[2] |
2
|
D0F8BF
|
Drug Info
|
IC50 = 0.25 nM
|
[2] |
3
|
D0HF1A
|
Drug Info
|
IC50 = 0.69 nM
|
[2] |
4
|
D0I9FU
|
Drug Info
|
IC50 = 0.88 nM
|
[2] |
Patent ID |
WO2015148350 |
Title |
Trka Kinase Inhibitors, Compositions and Methods Thereof. |
Abstract |
The present invention is directed to substituted five membered heteroaryl benzamide compounds of formula (I) (Formula (I)) which are tropomyosin-related kinase (Trk) family protein kinase inhibitors, and hence are useful in the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor TrkA. |
Applicant(s) |
Merck Sharp & Dohme Corp |
Representative Drug(s) |
D0T4CF |
Drug Info
|
IC50 = 0.37 nM |
Click to Show More |
[2] |
2
|
D04BRW
|
Drug Info
|
IC50 = 0.39 nM
|
[2] |
3
|
D0CY3U
|
Drug Info
|
IC50 = 0.76 nM
|
[2] |
Patent ID |
WO2015148344 |
Title |
Trka Kinase Inhibitors, Compositions and Methods Thereof. |
Abstract |
The present invention is directed to six membered heteroaryl benzamide compounds of formula (I), which are tropomyosin-related kinase (Trk) family protein kinase inhibitors, and hence are useful in the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor TrkA. |
Applicant(s) |
Merck Sharp & Dohme Corp |
Representative Drug(s) |
D0UN4M |
Drug Info
|
IC50 = 0.069 nM |
Click to Show More |
[2] |
2
|
D05MRY
|
Drug Info
|
IC50 = 0.083 nM
|
[2] |
3
|
D04JCD
|
Drug Info
|
IC50 = 0.23 nM
|
[2] |
Patent ID |
WO2015143654 |
Title |
Trka Kinase Inhibitors,Compositions and Methods Thereof. |
Abstract |
The present invention is directed to six membered heteroaryl benzamide compounds of formula (I) which are tropomyosin-related kinase (Trk) family protein kinase inhibitors, and hence are useful in the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor TrkA. |
Applicant(s) |
Merck Sharp & Dohme Corp |
Representative Drug(s) |
D0EC4Z |
Drug Info
|
IC50 = 0.6 nM |
Click to Show More |
[2] |
2
|
D0ZE6H
|
Drug Info
|
IC50 = 1 nM
|
[2] |
3
|
D07VFQ
|
Drug Info
|
IC50 = 1.3 nM
|
[2] |
4
|
D0H3ZG
|
Drug Info
|
IC50 = 1.5 nM
|
[2] |
Patent ID |
WO2015112445 |
Title |
6-Phenyl- or 6-(Pyridin-3-Yl)Indazole Derivatives and Methods of Use. |
Abstract |
Compounds of formula (I) and pharmaceutically acceptable salts, esters, amides, or radiolabelled forms thereof, wherein R1, R2, R3, R4, R5, R6, and X are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by Tropomysin receptor kinases (Trk). Methods for making the compounds are disclosed. Also disclosed are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions. |
Applicant(s) |
Abbvie Inc |
Representative Drug(s) |
D0J9ZG |
Drug Info
|
IC50 = 2.7 nM |
Click to Show More |
[1] |
2
|
D0V5AG
|
Drug Info
|
IC50 = 2.7 nM
|
[1] |
3
|
D0T2OX
|
Drug Info
|
IC50 = 3.4 nM
|
[1] |
Patent ID |
WO2015092610 |
Title |
N-Acylpiperidine Ether Tropomyosin-Related Kinase Inhibitors. |
Abstract |
The present invention relates to compounds of Formula (I) described herein and their pharmaceutically acceptable salts, and their use in medicine, in particular as Trk antagonists. |
Applicant(s) |
Pfizer Limited |
Representative Drug(s) |
D03BAY |
Drug Info
|
IC50 = 1.3 nM |
Click to Show More |
[2] |
2
|
D04GCC
|
Drug Info
|
IC50 = 1.5 nM
|
[2] |
3
|
D00FJH
|
Drug Info
|
IC50 = 1.7 nM
|
[2] |
4
|
D00XXZ
|
Drug Info
|
IC50 = 6 nM
|
[2] |
5
|
D0X1LP
|
Drug Info
|
IC50 = 12 nM
|
[2] |
6
|
D04RXX
|
Drug Info
|
IC50 = 290 nM
|
[2] |
Patent ID |
WO2015042088 |
Title |
Trka Kinase Inhibitors, Compositions and Methods Thereof. |
Abstract |
The present invention is directed to benzyl urea compounds of formula (I) which are tropomyosin-related kinase (Trk) family protein kinase inhibitors, and hence may be useful in the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor Trk-A, Trk-B and/or Trk-C. |
Applicant(s) |
Merck Sharp & Dohme Corp |
Representative Drug(s) |
D0U5XI |
Drug Info
|
IC50 = 27 nM |
Click to Show More |
[2] |
2
|
D0VD5J
|
Drug Info
|
IC50 = 28 nM
|
[2] |
3
|
D0M8VS
|
Drug Info
|
IC50 = 99 nM
|
[2] |
Patent ID |
WO2014078408 |
Title |
Bicyclic Heteroaryl Urea, Thiourea, Guanidine and Cyanoguanidine Compounds As Trka Kinase Inhibitors. |
Abstract |
Compounds of Formula I or stereoisomers, tautomers, or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein Ring A, Ring C and X are as defined herein, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis and pelvic pain syndrome. |
Applicant(s) |
Array Biopharma Inc |
Representative Drug(s) |
D0YN0I |
Drug Info
|
IC50 = 48 nM |
Click to Show More |
[2] |
2
|
D05AQT
|
Drug Info
|
IC50 = 82 nM
|
[2] |
Patent ID |
WO2013176970 |
Title |
Trka Kinase Inhibitors, Compositions and Methods Thereof. |
Abstract |
The present invention is directed to benzyl urea compounds, which are tropomyosin-related kinase (Trk) family protein kinase inhibitors, and hence may be useful in the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor Trk-A, Trk-B and/or Trk-C. |
Applicant(s) |
Merck Sharp & Dohme Corp |
Representative Drug(s) |
D0UQ2G |
Drug Info
|
IC50 = 6.5 nM |
Click to Show More |
[2] |
2
|
D0CG8N
|
Drug Info
|
IC50 = 11 nM
|
[2] |
Patent ID |
WO2013009582 |
Title |
Trka Kinase Inhibitors, Compositions and Methods Thereof. |
Abstract |
The present invention is directed to compounds of formula I and la: which are tropomyosin-related kinase (Trk) family protein kinase inhibitors, and hence are useful in the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor TrkA. |
Applicant(s) |
Merck Sharp & Dohme Corp |
Representative Drug(s) |
D0Y0XJ |
Drug Info
|
IC50 = 28 nM |
Click to Show More |
[2] |
2
|
D02ZQN
|
Drug Info
|
IC50 = 5400 nM
|
[2] |
Patent ID |
WO2012158413 |
Title |
Pyrrolidinyl Urea and Pyrrolidinyl Thiourea Compounds As Trka Kinase Inhibitors. |
Abstract |
Compounds of Formula I: or stereoisomers, tautomers, or pharmaceutically acceptable salts, or solvates or prodrugs thereof, where R1, R2, Ra, Rb, Rc, Rd, X, Y, B, and Ring C are as defined herein, and wherein the Y-B moiety and the NH-C(=X)-NH moiety are in the trans configuration, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation, neurodegenerative diseases and certain infectious diseases. |
Applicant(s) |
Array Biopharma Inc |
Representative Drug(s) |
D00ICS |
Drug Info
|
IC50 = 1 to 100 nM |
Click to Show More |
[1] |
2
|
D06YON
|
Drug Info
|
IC50 = 1 to 100 nM
|
[1] |
3
|
D0A4YR
|
Drug Info
|
IC50 = 1 to 100 nM
|
[1] |
4
|
D0I8AY
|
Drug Info
|
IC50 = 1 to 100 nM
|
[1] |
5
|
D0J5OO
|
Drug Info
|
IC50 = 1 to 100 nM
|
[1] |
6
|
D0JJ0T
|
Drug Info
|
IC50 = 1 to 100 nM
|
[1] |
7
|
D0K2GH
|
Drug Info
|
IC50 = 1 to 100 nM
|
[1] |
8
|
D0K3QT
|
Drug Info
|
IC50 = 1 to 100 nM
|
[1] |
9
|
D0LB7Z
|
Drug Info
|
IC50 = 1 to 100 nM
|
[1] |
10
|
D0ME5D
|
Drug Info
|
IC50 = 1 to 100 nM
|
[1] |
11
|
D0X0YJ
|
Drug Info
|
IC50 = 1 to 100 nM
|
[1] |
12
|
D0Z6LB
|
Drug Info
|
IC50 = 1 to 100 nM
|
[1] |
Patent ID |
WO2012137089 |
Title |
Pyrrolo [2, 3 -D] Pyrimidine Derivatives As Inhibitors of Tropomyosin- Related Kinases. |
Abstract |
The present invention relates to compounds of Formula (I) and their pharmaceutically acceptable salts, wherein the substituents are as described herein, and their use in medicine, in particular as Trk antagonists. |
Applicant(s) |
Pfizer Limited |
Representative Drug(s) |
D0AG2A |
Drug Info
|
IC50 = 4 nM |
Click to Show More |
[2] |
2
|
D0S0II
|
Drug Info
|
IC50 = 48 nM
|
[2] |
Patent ID |
WO2012125668 |
Title |
Trka Kinase Inhibitors, Compositions and Methods Thereof. |
Abstract |
The present invention is directed to quinazolinyl and pyridoquinazolinyl compounds of formula (I) which are tropomyosin-related kinase (Trk) family protein kinase inhibitors, and hence are useful in the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor TrkA. |
Applicant(s) |
Merck Sharp & Dohme Corp |
Representative Drug(s) |
D0U3RD |
Drug Info
|
IC50 = 0.7 nM |
Click to Show More |
[2] |
2
|
D0RR8O
|
Drug Info
|
IC50 = 1.5 nM
|
[2] |
Patent ID |
WO2011146336 |
Title |
Macrocyclic Compounds As Trk Kinase Inhibitors. |
Abstract |
Compounds of Formula I: and pharmaceutically acceptable salts thereof, wherein ring A, ring B, W, m, D, R2, R2a, R3, R3a, and Z are as defined herein, are inhibitors of Trk kinases and are useful in the treatment of pain, cancer, inflammation, neurodegenerative diseases and certain infectious diseases. |
Applicant(s) |
Array Biopharma Inc |
Representative Drug(s) |
D05KHT |
Drug Info
|
IC50 = 1 to 100 nM |
Click to Show More |
[1] |
2
|
D05RKT
|
Drug Info
|
IC50 = 1 to 100 nM
|
[1] |
3
|
D0Z5PA
|
Drug Info
|
IC50 = 1 to 100 nM
|
[1] |
Patent ID |
WO2011006074 |
Title |
Substituted Pyrazolo[1,5-A]Pyrimidine Compounds As Trk Kinase Inhibitors. |
Abstract |
Compounds of Formula (I) and salts thereof in which R1, R2, R3, R4, X, Y and n have the meanings given in the specification, are inhibitors of Trk kinases and are useful in the treatment of diseases which can be treated with a Trk kinase inhibitor such as pain, cancer, inflammation, neurodegenerative diseases and certain infectious diseases. |
Applicant(s) |
Array Biopharma Inc |
Representative Drug(s) |
D00DIZ |
Drug Info
|
IC50 = 1.7 nM |
Click to Show More |
[1] |
2
|
D0BI5I
|
Drug Info
|
IC50 = 6.6 nM
|
[1] |
3
|
D0BZ0T
|
Drug Info
|
IC50 = 16.1 nM
|
[1] |
4
|
D0H8XH
|
Drug Info
|
IC50 = 28.9 nM
|
[1] |
Patent ID |
WO2010106028 |
Title |
Use of A Kinase Inhibitor for The Treatment of Thymoma. |
Abstract |
The invention provides a low molecular weight ATP-competitive CDK inhibitor and TRKA inhibitor of formula (I) for use in the treatment of thymoma and thymic carcinoma. The compound can be administered together with one or more cytotoxic or cytostatic agents. |
Applicant(s) |
Nerviano Medical Sciences S.R.L |
Representative Drug(s) |
D0AU4G |
Drug Info
|
IC50 = 1 nM |
Click to Show More |
[2] |
2
|
D0O8SX
|
Drug Info
|
IC50 = 53 nM
|
[2] |
Patent ID |
WO2010048314 |
Title |
Substituted Pyrazolo[1,5-A]Pyrimidine Compounds As Trk Kinase Inhibitors. |
Abstract |
Compounds of Formula (I) in which R1, R2, R3, R4, X, Y and n have the meanings given in the specification, are inhibitors of Trk kinases and are useful in the treatment of diseases which can be treated with a Trk kinase inhibitor. |
Applicant(s) |
Array Biopharma Inc |
Representative Drug(s) |
D03USW |
Drug Info
|
IC50 = 6.2 nM |
Click to Show More |
[1] |
2
|
D09SYD
|
Drug Info
|
IC50 = 10.2 nM
|
[1] |
3
|
D08IWT
|
Drug Info
|
IC50 = 28.5 nM
|
[1] |
4
|
D04KQB
|
Drug Info
|
IC50 = 77.5 nM
|
[1] |
Patent ID |
WO2010033941 |
Title |
Substituted Imidazo[1,2B]Pyridazine Compounds As Trk Kinase Inhibitors. |
Abstract |
Compounds of Formula (I): in which R1, R2, R3, R4, X, Y and n have the meanings given in the specification, are inhibitors of Trk kinases and are useful in the treatment of diseases which can be treated with a Trk kinase inhibitor. |
Applicant(s) |
Array Biopharma Inc |
Representative Drug(s) |
D04QHI |
Drug Info
|
IC50 = 2.1 nM |
Click to Show More |
[1] |
2
|
D0FS4S
|
Drug Info
|
IC50 = 3.8 nM
|
[1] |
3
|
D0W0UF
|
Drug Info
|
IC50 = 5.5 nM
|
[1] |
4
|
D0DO4I
|
Drug Info
|
IC50 = 15.5 nM
|
[1] |
Patent ID |
WO2010077680 |
Title |
Compositions of Protein Receptor Tyrosine Kinase Inhibitors. |
Abstract |
The present invention relates to novel synthetic substituted heterocyclic compounds and pharmaceutical compositions containing the same that are capable of inhibiting or antagonizing a family of receptor tyrosine kinases, Tropomysosin Related Kinases (Trk), in particular the nerve growth factor (NGF) receptor, TrkA. The invention further concerns the use of such compounds in the treatment and/or prevention of pain, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, or a disease, disorder or injury relating to dysmyelination or demyelination or the disease or disorder associated with abnormal activities of NGF recptor TrkA. |
Applicant(s) |
WU, Jay Jie-Qiang et al |
Representative Drug(s) |
D0PY0G |
Drug Info
|
IC50 = 85 nM |
Click to Show More |
[2] |
2
|
D07KVL
|
Drug Info
|
N.A.
|
[2] |
3
|
D0F2BF
|
Drug Info
|
N.A.
|
[2] |
4
|
D0FL8A
|
Drug Info
|
N.A.
|
[2] |
5
|
D0J4CA
|
Drug Info
|
N.A.
|
[2] |
6
|
D0K6IM
|
Drug Info
|
N.A.
|
[2] |
7
|
D0T0HM
|
Drug Info
|
N.A.
|
[2] |
Patent ID |
WO2016036796 |
Title |
Cyclic Urea Compounds As Tropomyosin-Related Kinase (Trk) Inhibitors. |
Abstract |
Tropomyosin-related kinase inhibitors (Trk inhibitors) are small molecule compounds useful in the treatment of disease. Trk inhibitors can be used as pharmaceutical agents and in pharmaceutical compositions. Trk inhibitors are useful in the treatment of inflammatory diseases, autoimmune disease, defects of bone metabolism and/or cancer, and are particularly useful in the treatment of osteoarthritis (OA), pain, and pain associated with OA. Trk inhibitors are also useful for inhibiting tropomyosin-related kinase A (TrkA), tropomyosin-receptor kinase B (TrkB), tropomyosin-receptor kinase C (TrkC), and/or c-FMS (the cellular receptor for colony stimulating factor-1 (CSF-1)). |
Applicant(s) |
Genzyme Corporation |
Representative Drug(s) |
D02QWP |
Drug Info
|
N.A. |
Click to Show More |
[1] |
2
|
D0I5DM
|
Drug Info
|
N.A.
|
[1] |
Patent ID |
WO2014078331 |
Title |
N-(Arylalkyl)-N'-Pyrazolyl-Urea, Thiourea, Guanidine and Cyanoguanidine Compounds As Trka Kinase Inhibitors. |
Abstract |
Compounds of Formula I or stereoisomers, tautomers, or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein Ring A, Ring C, X, Ra, Rb, Rc, Rd and n are as defined herein, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis or pelvic pain syndrome. |
Applicant(s) |
Array Biopharma Inc |
Representative Drug(s) |
D0W9RH |
Drug Info
|
N.A. |
Click to Show More |
[1] |
2
|
D0YM2S
|
Drug Info
|
N.A.
|
[1] |
Patent ID |
WO2013183578 |
Title |
Imidazo[1,2-B]Pyridazine Derivative As Kinase Inhibitor. |
Abstract |
The present invention provides a compound useful in treating tumors by ROS1 kinase enzyme activity inhibitory action and NTRK kinase enzyme inhibitory action, or a pharmacologically acceptable salt thereof. A compound having an imidazo[1,2-b]pyridazine structure represented by general formula (I), a pharmacologically acceptable salt thereof, or pharmaceutical compositions comprising such compounds. (In the formula, R1, G, T, Y1, Y2, Y3, and Y4 are as defined in the present description.). |
Applicant(s) |
Daiichi Sankyo Co., Ltd |
Representative Drug(s) |
D0M8UO |
Drug Info
|
N.A. |
Click to Show More |
[1] |
2
|
D0N1CF
|
Drug Info
|
N.A.
|
[1] |
3
|
D0T8XD
|
Drug Info
|
N.A.
|
[1] |
Patent ID |
WO2010144522 |
Title |
Ureidophenyl Substituted Triazine Derivatives and Their Therapeutical Applications. |
Abstract |
The present invention provides Uredophenyl substituted triazine derivatives and provides methods of using these compounds to modulate protein kinases and methods of using these compounds to treat protein kinase mediated diseases and conditions. |
Applicant(s) |
Abraxis Bioscience, Llc |
Representative Drug(s) |
D08SDJ |
Drug Info
|
N.A. |
Click to Show More |
[1] |
2
|
D0V7QU
|
Drug Info
|
N.A.
|
[1] |
Patent ID |
WO2016061228 |
Title |
Inhibition of Trk Kinase Mediated Tumor Growth and Disease Progression. |
Abstract |
It has been shown that Compound 1 unexpectedly and potently inhibits TRK kinases, including all three forms of TRK: NTRKl, NTRK2, and NTRK3. Additionally it has been shown that Compound 1 potently inhibits oncogenic mutated forms of TRK kinases, including fusion proteins. By way of exemplification, Compound 1 potently inhibits the NTRKl oncogenic fusion protein TPM3/NTRK1 in cellular assays. Compound 1 inhibits TRK kinase mediated tumor growth in vivo in a TPM3/NTRK1 xenograft model. |
Applicant(s) |
Deciphera Pharmaceuticals, Llc |
Representative Drug(s) |
D0FA6S |
Drug Info
|
IC50 = 3.8 nM |
[1] |
Patent ID |
WO2016009296 |
Title |
N-Acylpiperidine Ether Tropomyosin-Related Kinase Inhibitors. |
Abstract |
The present invention relates to compounds of Formula (I) described herein and their pharmaceutically acceptable salts, and their use in medicine, in particular as Trkantagonists. |
Applicant(s) |
Pfizer Inc |
Representative Drug(s) |
D02OLJ |
Drug Info
|
IC50 = 4.9 nM |
[2] |
Patent ID |
WO2015170218 |
Title |
Tropomyosin-Related Kinase Inhibitors. |
Abstract |
The present invention relates to compounds of Formula I and their pharmaceutically acceptable salts, wherein the substituents are as described herein, and their use in medicine, in particular as TrkA antagonists. |
Applicant(s) |
Pfizer Inc |
Patent ID |
WO2015089139 |
Title |
Tropomyosin-Related Kinase (Trk) Inhibitors. |
Abstract |
Tropomyosin-related kinase inhibitors (Trk inhibitors) are small molecule compounds useful in the treatment of disease. Trk inhibitors can be used as pharmaceutical agents and in pharmaceutical compositions. Trk inhibitors are useful in the treatment of inflammatory diseases, autoimmune disease, defects of bone metabolism and/or cancer, and are particularly useful in the treatment of osteoarthritis (OA), pain, and pain associated with OA. Trk inhibitors are also useful for inhibiting tropomyosin-related kinase A (TrkA), tropomyosin-related kinase B (TrkB), tropomyosin-related kinase C (TrkC), and/or c-FMS (the cellular receptor for colony stimulating factor-1 (CSF-1)). |
Applicant(s) |
Genzyme Corporation |
Representative Drug(s) |
D07RLB |
Drug Info
|
IC50 = 0.3 nM |
[1] |
Patent ID |
WO2014177510 |
Title |
Polymer Conjugates of Indolocarbazole Compounds In The Treatment of Pruritus. |
Abstract |
The present invention is directed to the novel use of polymer conjugates of a class of indolocarbazole compounds for the prevention, alleviation or/and treatment of pruritus, particularly of pruritus associated with or caused by dermatological diseases. |
Applicant(s) |
Creabilis Sa |
Patent ID |
WO2014129431 |
Title |
Trk-Inhibiting Compound. |
Abstract |
The invention provides a drug having as the active ingredient a compound having Trk-inhibiting activity in the prevention and/or treatment of Trk-associated diseases, for example, pain, pruritus, lowe. |
Applicant(s) |
Ono Pharmaceutical Co., Ltd |
Representative Drug(s) |
D0QT8L |
Drug Info
|
IC50 = 1 nM |
[2] |
Patent ID |
WO2014053968 |
Title |
Pyrrolo[3,2-C]Pyridine Tropomyosin-Related Kinase Inhibitors. |
Abstract |
The present invention relates to compounds of Formula (I) and their pharmaceutically acceptable salts, wherein the substituents are as described herein, and their use in medicine, in particular as Trk antagonists. |
Applicant(s) |
Pfizer Limited |
Representative Drug(s) |
D0DQ5G |
Drug Info
|
IC50 = 4.4 nM |
[2] |
Patent ID |
WO2014053965 |
Title |
Tropomyosin-Related Kinase Inhibitors. |
Abstract |
The present invention relates to compounds of Formula (IA) and (IB) and their pharmaceutically acceptable salts, wherein the substituents are as described herein, and their use in medicine, in particular as Trk antagonists. |
Applicant(s) |
Pfizer Limited |
Representative Drug(s) |
D0RK6W |
Drug Info
|
IC50 = 17 nM |
[2] |
Patent ID |
WO2014016434 |
Title |
Derivatives of Azaindazole or Diazaindazole Type for Treating A Cancer Overexpressing Trk. |
Abstract |
The present invention relates to a compound of following formula (I) or a pharmaceutically acceptable salt or solvate of same, a tautomer of same, or a stereoisomer or mixture of stereoisomers of same in any proportions, such as a mixture of enantiomers, notably a racemic mixture, as well as pharmaceutical composition comprising such a compound, for use in the treatment of a cancer associated with the overexpression of at least one Trk protein. |
Applicant(s) |
Pierre Fabre Medicament |
Representative Drug(s) |
D0Y1NH |
Drug Info
|
IC50 = 45 nM |
[2] |
Patent ID |
WO2013161919 |
Title |
Trk-Inhibiting Compound. |
Abstract |
The purpose of the present invention is to provide is a drug the active ingredient of which is a compound that has Trk-inhibiting activity in the prevention and/or treatment of diseases such as pain, pruritus, lower urinary tract disorder, asthma, allergic rhinitis, inflammatory bowel disease and Chagas disease. A compound represented by general formula (I) (where each symbol has the same definition as the symbol described in the Specification), a salt thereof, an N-oxide thereof, or a solvate thereof, or a prodrug of the same, is useful as a drug ingredient having Trk-inhibiting activity in the prevention and/or treatment of disease such as pain, pruritus, lower urinary tract disorder, asthma, allergic rhinitis, inflammatory bowel disease and Chagas disease. |
Applicant(s) |
Ono Pharmaceutical Co., Ltd |
Representative Drug(s) |
D0I2OO |
Drug Info
|
IC50 = 2 nM |
[2] |
Patent ID |
WO2013088256 |
Title |
Substituted Pyrazolo[1,5-A] Pyridine As Tropomyosin Receptor Kinase (Trk) Inhibitors. |
Abstract |
The present application relates to a series of substituted pyrazolo[1,5-a]pyridine compounds, their use as tropomyosin receptor kinase (Trk) family protein kinase inhibitors., method of making and pharmaceutical compositions comprising such compounds. |
Applicant(s) |
Dr. Reddy'S Laboratories Ltd |
Representative Drug(s) |
D0DN3Q |
Drug Info
|
IC50 < 50 nM |
[2] |
Patent ID |
WO2013074518 |
Title |
Modulating Certain Tyrosine Kinases. |
Abstract |
The present invention provides therapeutic and diagnostic modalities relevant to treating disorders associated with tyrosine kinase actvity. |
Applicant(s) |
Tesaro, Inc |
Representative Drug(s) |
D0T3TZ |
Drug Info
|
IC50 < 3 nM |
[1] |
Patent ID |
WO2013026021 |
Title |
Trka As A Target for Inhibiting App Cleavage and/or Progression of Alzheimer'S Disease. |
Abstract |
In various embodiments method are provided for inhibiting (partially or fully) the C-terminal cleavage of APP resulting in the formation of APP-C31 peptide and APPneo (APP664) in a mammal. The methods typically involve administering or causing to be administered to the mammal a TrkA kinase inhibitor in an amount sufficient to reduce C-terminal cleavage of APP and production of a C31 peptide and/or APPneo. In certain embodiments the inhibitor comprises ADDN-1351 or a derivative thereof. |
Applicant(s) |
Buck Institute for Research On Aging |
Representative Drug(s) |
D06STX |
Drug Info
|
IC50 = 700 nM |
[1] |
Patent ID |
WO2012125667 |
Title |
Trka Kinase Inhibitors, Compositions and Methods Thereof. |
Abstract |
The present invention is directed to pyridotriazole and benztriazole compounds of formula (I) (I) which are tropomyosin-related kinase (Trk) family protein kinase inhibitors, and hence are useful in the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor TrkA. |
Applicant(s) |
Merck Sharp & Dohme Corp |
Representative Drug(s) |
D0MZ7K |
Drug Info
|
IC50 = 27 nM |
[2] |
Patent ID |
WO2007022999 |
Title |
Polymer Conjugates of K-252A and Derivatives Thereof. |
Abstract |
The present invention relates to novel polymer conjugates of K-252a and derivatives thereof and to their use for the preparation of a pharmaceutical composition useful for the prevention, alleviation and treatment of kinase-associated pathologies. In particular, the present invention relates to the prevention, alleviation and treatment of HMGB1-associated pathologies. In a particular aspect, the invention relates to the use of the novel polymer conjugates of K-252a and derivatives thereof in the preparation of a pharmaceutical composition useful for the prevention, alleviation and treatment of neurological disorders, neuropathies and neurodegenerative disorders of the central and peripheral nervous system. In a further preferred aspect, the invention relates to the use of the polymer conjugates in the preparation of a pharmaceutical composition useful for the prevention, alleviation and treatment of dermal pathologies, in particular dermal pathologies associated with an excessive keratinocyte proliferation, in particular psoriasis. In a still further aspect, the invention relates to the use of the polymer conjugates in the prevention, alleviation and treatment of NGF-related pain. More specifically, the present invention relates to a polymer conjugate of K-252a and derivatives thereof, wherein the polymer is polyethylene glycol or methoxy-polyethylene glycol formula (I). |
Applicant(s) |
Creabilis Therapeutics Spa Traversa, et al |
Patent ID |
WO2014053967 |
Title |
Pyrrolo[2,3-D]Pyrimidine Tropomyosin-Related Kinase Inhibitors. |
Patent ID |
WO2015200341 |
Title |
Substituted Imidazo[1,2-A]Pyridine Compounds Useful for The Treatment of Pain. |
Abstract |
The present application relates to a series of substituted imidazo[l,2-a]pyridine compounds of formula (I), pharmaceutically acceptable salts, pharmaceutically acceptable solvates or stereoisomers thereof, their use as tropomyosin receptor kinase (Trk) family protein kinase inhibitors, method of making and pharmaceutical compositions comprising such compounds. |
Applicant(s) |
Dr. Reddy'S Laboratories Ltd |
Representative Drug(s) |
D0WI7N |
Drug Info
|
N.A. |
[2] |
Patent ID |
WO2014152663 |
Title |
Crystalline forms of Tyrosine Kinase Inhibitors and Their Salts. |
Abstract |
The invention relates to various polymorphic forms and amorphous form of sodium 4-((3-(4-cyclohexylpiperazin-1-yl)-6-oxo-6H-anthra[1,9-cd]isoxazol-5-yl)amino)benzate, including the polymorphic form A, mixtures of the polymorphs, process for the preparation thereof and the use thereof in a pharmaceutical composition containing thereof. |
Applicant(s) |
Mundipharma International Corporation Limited |
Representative Drug(s) |
D02ETU |
Drug Info
|
N.A. |
[2] |
Patent ID |
WO2014078417 |
Title |
Pyrazolyl Urea, Thiourea, Guanidine and Cyanoguanidine Compounds As Trka Kinase Inhibitors. |
Abstract |
Compounds of Formula I: or stereoisomers, tautomers, or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein Ring A, Ring C and X are as defined herein, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis or pelvic pain syndrome. |
Applicant(s) |
Array Biopharma Inc |
Representative Drug(s) |
D0BP9B |
Drug Info
|
N.A. |
[1] |
Patent ID |
WO2014078325 |
Title |
N-(Monocyclic Aryl),N'-Pyrazolyl-Urea, Thiourea, Guanidine and Cyanoguanidine Compounds As Trka Kinase Inhibitors. |
Abstract |
Compounds of Formula (I) or stereoisomers, tautomers, or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein Ring A, Ring C and X are as defined herein, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis or pelvic pain syndrome. |
Applicant(s) |
Array Biopharma Inc |
Representative Drug(s) |
D05NBR |
Drug Info
|
N.A. |
[1] |
Patent ID |
WO2014078322 |
Title |
Thiazolyl and Oxazolyl Urea, Thiourea, Guanidine and Cyanoguanidine Compounds As Trka Kinase Inhibitors. |
Abstract |
Compounds of Formula (I) or stereoisomers, tautomers, or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein Ring A, Ring C and X are as defined herein, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis or pelvic pain syndrome. |
Applicant(s) |
Array Biopharma Inc |
Representative Drug(s) |
D0JU4R |
Drug Info
|
N.A. |
[1] |
Patent ID |
WO2013088257 |
Title |
Substituted Heterocyclic Compounds As Tropomyosin Receptor Kinase A (Trka) Inhibitors. |
Abstract |
The present application relates to a series of substituted pyrazolo[l,5-a]pyridine compounds, their use as tropomyosin receptor kinase (Trk) family protein kinase inhibitors, method of making and pharmaceutical compositions comprising such compounds. |
Applicant(s) |
Dr. Reddy'S Laboratories Ltd |
Representative Drug(s) |
D0V9ZJ |
Drug Info
|
N.A. |
[2] |
Patent ID |
WO2000043384 |
Title |
Aromatic Heterocyclic Compounds As Antiinflammatory Agents. |
Abstract |
Disclosed are novel aromatic heterocyclic compounds of formula (I) wherein Ar1, Ar2, L, Q and X are described herein. The compounds are useful in pharmaceutic compositions for treating diseases or pathological conditions involving inflammation such as chronic inflammatory diseases. Also disclosed are processes of making such compounds. |
Applicant(s) |
Boehringer Ingelheim Pharmaceuticals, Inc |
Patent ID |
WO2012116217 |
Title |
Compounds and Compositions As Trk Inhibitors. |
Abstract |
The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated TRK kinase activity. |
Applicant(s) |
Irm Llc |
Patent ID |
WO2012034095 |
Title |
Compounds and Compositions As Trk Inhibitors. |
Abstract |
The invention provides compounds of formula (I), pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated TRK kinase activity. wherein: and the rest of the variables are as specified in the claims. |
Applicant(s) |
Irm Llc |
Patent ID |
WO2012034091 |
Title |
Imidazo [1, 2] Pyridazin Compounds and Compositions As Trk Inhibitors. |
Abstract |
The invention provides compounds of formula (I), pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated TRK kinase activity. |
Applicant(s) |
Irm Llc |
United States Patent and Trademark Office (USPTO) |
Patent ID |
US20040002145 |
Title |
Crystal Structure of Liganded Cfms Kinase Domain. |
Representative Drug(s) |
D0X9VS |
Drug Info
|
N.A. |
[1] |